We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Watchful Waiting. An Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00952926
First Posted: August 6, 2009
Last Update Posted: May 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Vejle Hospital
  Purpose
The purpose of this study is to investigate if operation and permanent stoma can be omitted in patients with cancer in the lower part of the rectum.

Condition
Rectal Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy

Further study details as provided by Vejle Hospital:

Primary Outcome Measures:
  • Frequency of local recurrence [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Frequency of cumulative local recurrence [ Time Frame: Up to 5 years ]
  • Frequency of distant metastases verified by planned PET/CT scans [ Time Frame: Up to 5 years. ]
  • Overall survival [ Time Frame: Up to 5 years. ]

Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Study Completion Date: December 2018
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Patients entering this study are offered the possibility of avoiding an extensive operation and a permanent stoma.

Over the past 2 years Vejle Hospital examined patients with rectal cancer during their course of treatment and we have developed a method to predict complete response.

Patients in this study are treated with chemotherapy and external irradiation supplemented with an endorectal boost (2 fractions). At the start of treatment and weeks 2, 4, and 6 of the treatment course an endoscopy is performed to evaluate the response. The final evaluation is performed 6 weeks after end of treatment. Patients with complete remission are offered observation. Patients with residual tumor are advised to be operated.

Follow-up is performed every 2 months the first year and every 3 months the second year. 2 follow-up visits are planned for the third year. A yearly follow-up is scheduled for the fourth and fifth year.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients referred from surgical departments in Denmark.
Criteria

Inclusion Criteria:

  • Histopathologically verified adenocarcinoma in the rectum
  • Planned APR or ultra low resection
  • Primary resectable T2 or T3 tumor
  • Distance from anus to lower edge of tumor ≤ 6 cm
  • Suited for curative intended radiation and chemotherapy
  • Accept taking of biopsy and blood samples for translational research
  • Age ≥ 18 years
  • Normal function of bone marrow

    • leukocytes ≥ 3 x 10^9/l
    • thrombocytes ≥ 100
  • Normal liver function

    • ALAT < 2.5 x upper normal value
    • bilirubin < 2.5 x upper normal value
  • Renal function

    • Serum creatinin < 1.5 x upper normal value
  • Written and orally informed consent

Exclusion Criteria:

  • Other malignant disease within the last 5 years apart from basocellular skin cancer and carcinoma in situ cervicis uteri
  • Distant metastases
  • Pregnant or breast feeding patients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00952926


Locations
Denmark
Vejle Hospital
Vejle, Denmark, DK-7100
Sponsors and Collaborators
Vejle Hospital
Investigators
Principal Investigator: Anders Jakobsen, DMSc Vejle Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Vejle Hospital
ClinicalTrials.gov Identifier: NCT00952926     History of Changes
Other Study ID Numbers: S-20090063
First Submitted: August 3, 2009
First Posted: August 6, 2009
Last Update Posted: May 30, 2017
Last Verified: May 2017

Keywords provided by Vejle Hospital:
Watchful Waiting
Rectal cancer
Observation
Avoid operation

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases